Association between Serum Ferritin Levels and Metabolic-associated Fatty Liver Disease in Adults: a Cross-sectional Study Based on the NHANES

Abstract

Objective

Ferritin, initially acting as an iron-storage protein, was found to be associated with metabolic diseases. Our study was designed to investigate the association between serum ferritin and metabolic-associated fatty liver disease (MAFLD) using data from the National Health and Nutrition Examination Survey (NHANES) of the United State of America.

Methods

A cross-sectional study was conducted, enrolling a total of 2145 participants from the NHANES in the 2017–2018 cycles. Hepatic steatosis and liver fibrosis were assessed by ultrasound images and several non-invasive indexes. Multiple regression analysis was conducted to determine the associations between serum ferritin concentration and MAFLD and liver fibrosis.

Results

The analysis revealed that participants with higher serum ferritin levels (Q3 and Q4 groups) had a higher prevalence of MAFLD than those with the lowest serum ferritin levels [Q3 vs. Q1: OR=2.17 (1.33, 3.53), P<0.05 in fatty liver index (FLI); Q4 vs. Q1: OR=3.13 (1.91, 5.13), P<0.05 in FLI]. Additionally, participants with the highest serum ferritin levels (Q4 group) displayed a higher prevalence of liver fibrosis [Q4 vs. Q1: OR=2.59 (1.19, 5.62), P<0.05 in liver stiffness measurement; OR=5.06 (1.12, 22.94), P<0.05 in fibrosis-4 index], with significantly increased risk observed in participants with concomitant diabetes [OR=7.45 (1.55, 35.72), P=0.012].

Conclusion

Our study revealed that elevated serum ferritin levels are associated with a higher prevalence of MAFLD and advanced liver fibrosis in patients. Elevated serum ferritin levels combined with diabetes are important risk factors for liver fibrosis.

Keywords

serum ferritin / liver fibrosis / metabolic-associated fatty liver disease / National Health and Nutrition Examination Survey

References

[1] LudwigJ, ViggianoTR, McGillDB, et al.. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc, 1980, 55(7): 434-438

[2] ByrneCD, TargherG. NAFLD: a multisystem disease. J Hepatol, 2015, 62(1): S47-S64 Suppl

[3] EslamM, SanyalAJ, GeorgeJ, et al.. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology, 2020, 158(7): 1999-2014.e1

[4] EslamM, NewsomePN, SarinSK, et al.. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol, 2020, 73(1): 202-209

[5] WangTY, GeorgeJ, ZhengMH. Metabolic (dysfunction) associated fatty liver disease: more evidence and a bright future. Hepatobiliary Surg Nutr, 2021, 10(6): 849-852

[6] NguyenVH, LeMH, CheungRC, et al.. Differential Clinical Characteristics and Mortality Outcomes in Persons With NAFLD and/or MAFLD. Clin Gastroenterol Hepatol, 2021, 19(10): 2172-2181.e6

[7] LimGEH, TangA, NgCH, et al.. An Observational Data Meta-analysis on the Differences in Prevalence and Risk Factors Between MAFLD vs NAFLD. Clin Gastroenterol Hepatol, 2023, 21(3): 619-629.e7

[8] CiardulloS, PerseghinG. Prevalence of NAFLD, MAFLD and associated advanced fibrosis in the contemporary United States population. Liver Int, 2021, 41(6): 1290-1293

[9] WangW, KnovichMA, CoffmanLG, et al.. Serum ferritin: Past, present and future. Biochim Biophys Acta, 2010, 1800(8): 760-769

[10] GranickS, MichaelisL. Ferritin and Apoferritin. Science, 1942, 95(2469): 439-440

[11] BirgegardG, HallgrenR, KillanderA, et al.. Serum ferritin during infection. A longitudinal study. Scand J Haematol, 1978, 21(4): 333-340

[12] MahroumN, AlghoryA, KiyakZ, et al.. Ferritin–from iron, through inflammation and autoimmunity, to COVID-19. J Autoimmun, 2022, 126: 102778

[13] RuddellRG, Hoang-LeD, BarwoodJM, et al.. Ferritin functions as a proinflammatory cytokine via iron-independent protein kinase C zeta/nuclear factor kappaB-regulated signaling in rat hepatic stellate cells. Hepatology, 2009, 49(3): 887-900

[14] CorradiniE, BuzzettiE, DongiovanniP, et al.. Ceruloplasmin gene variants are associated with hyperferritinemia and increased liver iron in patients with NAFLD. J Hepatol, 2021, 75(3): 506-513

[15] KatsarouMS, PapasavvaM, LatsiR, et al.. Hemochromatosis: Hereditary hemochromatosis and HFE gene. Vitam Horm, 2019, 110: 201-222

[16] JungJY, ShimJJ, ParkSK, et al.. Serum ferritin level is associated with liver steatosis and fibrosis in Korean general population. Hepatol Int, 2019, 13(2): 222-233

[17] ManousouP, KalambokisG, GrilloF, et al.. Serum ferritin is a discriminant marker for both fibrosis and inflammation in histologically proven non-alcoholic fatty liver disease patients. Liver Int, 2011, 31(5): 730-739

[18] AvilaF, EcheverriaG, PerezD, et al.. Serum Ferritin Is Associated with Metabolic Syndrome and Red Meat Consumption. Oxid Med Cell Longev, 2015, 2015: 769739

[19] Al AklNS, KhalifaO, ErrafiiK, et al.. Association of dyslipidemia, diabetes and metabolic syndrome with serum ferritin levels: a middle eastern population-based cross-sectional study. Sci Rep, 2021, 11(1): 24080

[20] Suarez-OrtegonMF, Ensaldo-CarrascoE, ShiT, et al.. Ferritin, metabolic syndrome and its components: A systematic review and meta-analysis. Atherosclerosis, 2018, 275: 97-106

[21] AbdesselamA, ZidoumH, ZadjaliF, et al.. Estimate of the HOMA-IR Cut-off Value for Identifying Subjects at Risk of Insulin Resistance Using a Machine Learning Approach. Sultan Qaboos Univ Med J, 2021, 21(4): 604-612

[22] WongVW, AdamsLA, de LedinghenV, et al.. Noninvasive biomarkers in NAFLD and NASH - current progress and future promise. Nat Rev Gastroenterol Hepatol, 2018, 15(8): 461-478

[23] EddowesPJ, SassoM, AllisonM, et al.. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology, 2019, 156(6): 1717-1730

[24] BedogniG, BellentaniS, MiglioliL, et al.. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol, 2006, 6: 33

[25] RoulotD, CzernichowS, Le ClesiauH, et al.. Liver stiffness values in apparently healthy subjects: influence of gender and metabolic syndrome. J Hepatol, 2008, 48(4): 606-613

[26] AnguloP, HuiJM, MarchesiniG, et al.. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology, 2007, 45(4): 846-854

[27] Vallet-PichardA, MalletV, NalpasB, et al.. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology, 2007, 46(1): 32-36

[28] von ElmE, AltmanDG, EggerM, et al.. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet, 2007, 370(9596): 1453-1457

[29] WangH, SunR, YangS, et al.. Association between serum ferritin level and the various stages of non-alcoholic fatty liver disease: A systematic review. Front Med (Lausanne), 2022, 9: 934989

[30] EtminaniR, ManafZA, ShaharS, et al.. Predictors of Nonalcoholic Fatty Liver Disease Among Middle-Aged Iranians. Int J Prev Med, 2020, 11: 113

[31] KowdleyKV, BeltP, WilsonLA, et al.. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology, 2012, 55(1): 77-85

[32] FahmyM, YoungSP. Modulation of iron metabolism in monocyte cell line U937 by inflammatory cytokines: changes in transferrin uptake, iron handling and ferritin mRNA. Biochem J, 1993, 296(1): 175-181

[33] TranTN, EubanksSK, SchafferKJ, et al.. Secretion of ferritin by rat hepatoma cells and its regulation by inflammatory cytokines and iron. Blood, 1997, 90(12): 4979-4986

[34] KanamoriY, MurakamiM, SugiyamaM, et al.. Hepcidin and IL-1beta. Vitam Horm, 2019, 110: 143-156

[35] KanamoriY, MurakamiM, SugiyamaM, et al.. Interleukin-1beta (IL-1beta) transcriptionally activates hepcidin by inducing CCAAT enhancer-binding protein delta (C/EBPdelta) expression in hepatocytes. J Biol Chem, 2017, 292(24): 10275-10287

[36] HeYJ, LiuXY, XingL, et al.. Fenton reaction-independent ferroptosis therapy via glutathione and iron redox couple sequentially triggered lipid peroxide generator. Biomaterials, 2020, 241: 119911

[37] WinterbournCC. Toxicity of iron and hydrogen peroxide: the Fenton reaction. Toxicol Lett, 1995, 82–83: 969-974

[38] HandaP, ThomasS, Morgan-StevensonV, et al.. Iron alters macrophage polarization status and leads to steatohepatitis and fibrogenesis. J Leukoc Biol, 2019, 105(5): 1015-1026

[39] QuW, MaT, CaiJ, et al.. Liver Fibrosis and MAFLD: From Molecular Aspects to Novel Pharmacological Strategies. Front Med (Lausanne), 2021, 8: 761538

[40] SakuraiY, KubotaN, YamauchiT, et al.. Role of Insulin Resistance in MAFLD. Int J Mol Sci, 2021, 22(8): 4156

[41] BackeMB, MoenIW, EllervikC, et al.. Iron Regulation of Pancreatic Beta-Cell Functions and Oxidative Stress. Annu Rev Nutr, 2016, 36: 241-273

[42] HansenJB, TonnesenMF, MadsenAN, et al.. Divalent metal transporter 1 regulates iron-mediated ROS and pancreatic beta cell fate in response to cytokines. Cell Metab, 2012, 16(4): 449-461

[43] GabrielsenJS, GaoY, SimcoxJA, et al.. Adipocyte iron regulates adiponectin and insulin sensitivity. J Clin Invest, 2012, 122(10): 3529-3540

[44] AltamuraS, MudderK, SchlottererA, et al.. Iron aggravates hepatic insulin resistance in the absence of inflammation in a novel db/db mouse model with iron overload. Mol Metab, 2021, 51: 101235

[45] IkedaY, WatanabeH, ShiuchiT, et al.. Deletion of H-ferritin in macrophages alleviates obesity and diabetes induced by high-fat diet in mice. Diabetologia, 2020, 63(8): 1588-1602

[46] MorwaldK, AignerE, BergstenP, et al.. Serum Ferritin Correlates With Liver Fat in Male Adolescents With Obesity. Front Endocrinol (Lausanne), 2020, 11: 340

[47] GongL, YuanF, TengJ, et al.. Weight loss, inflammatory markers, and improvements of iron status in overweight and obese children. J Pediatr, 2014, 164(4): 795-800.e2

[48] Tussing-HumphreysLM, NemethE, FantuzziG, et al.. Decreased serum hepcidin and improved functional iron status 6 months after restrictive bariatric surgery. Obesity (Silver Spring), 2010, 18(10): 2010-2016

[49] HoylesL, Fernandez-RealJM, FedericiM, et al.. Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women. Nat Med, 2018, 24(7): 1070-1080

[50] Mayneris-PerxachsJ, CardelliniM, HoylesL, et al.. Iron status influences non-alcoholic fatty liver disease in obesity through the gut microbiome. Microbiome, 2021, 9(1): 104

[51] LiX, LiangH. Effects of Lactobacillus casei on Iron Metabolism and Intestinal Microflora in Rats Exposed to Alcohol and Iron. Turk J Gastroenterol, 2022, 33(6): 470-476